George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (10.345%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 30.50
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update & Notice of Results

22 May 2023 07:00

RNS Number : 0937A
Ilika plc
22 May 2023
 

 

Ilika plc

("Ilika" or the "Company")

 

Trading Update & Notice of Results

 

Analyst and Investor presentations

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, provides an update on trading, Stereax® manufacturing, and Goliath product development, as well as issuing its notice of full year results for the year ended 30 April 2023.

 

Trading Update for FY23

Unaudited trading for the year ended 30 April 2023 has been in line with management expectations. The Company expects to announce revenues of approximately £0.8m (2022: £0.5m), and an EBITDA loss excluding share-based payments of approximately £7.0m (2022: EBITDA loss of £6.4m). Cash and cash equivalents at the period end were £15.8m (30 April 2022: £23.4m).

Stereax  Manufacturing Update

Following initial process qualification at its Stereax manufacturing facility in the UK, Ilika has been improving process yield and qualifying initial product batches. This enabled Ilika to release its first customer shipment of Stereax M50 cells in April 2023. The M50 cells can be used individually, but they are also the building blocks for Ilika's M300 batteries, which are made from six M50 cells connected in parallel. Ilika shipped its first batch of M300 batteries to customers earlier this month.

 

Ilika has 23 commercial orders from 20 customers, with miniature medical devices making up the majority of the demand. The applications cover 11 active implantable medical devices, three smart dental devices, two smart lenses, one for aerospace and three others.

 

Further to Ilika's announcement in January 2023, Ilika and Cirtec Medical LLC ('Cirtec'), a strategic outsourcing partner of complex medical devices including minimally invasive and active implantable devices, are currently finalising the terms of their intended partnership. Ilika and Cirtec have signed a memorandum of understanding ('MOU') which outlines the transfer of Stereax® mm-scale battery manufacturing to Cirtec's facility in Lowell, Massachusetts, U.S. Following the transfer, Ilika will focus on advanced technology development and IP licensing in support of Cirtec's manufacturing and commercialisation activities.

 

Goliath Progress Update

Product development of Goliath, Ilika's large format battery for electric vehicles and consumer appliances, has continued to progress to schedule. Building on the significant improvement achieved in energy density (providing the potential for lighter weight battery packs) in the first half of the year, Ilika has focussed on increasing cycle life.

 

In parallel, Ilika has continued carrying out scale-up studies with partners to ensure its process is as compatible as possible with existing Gigafactory assets. In particular, Ilika has completed an equipment design study with Comau, an economic feasibility study with the UK Battery Industrialisation Centre (UKBIC) and is currently executing a series of trials on production-ready equipment. 

 

Ilika continues to explore opportunities for closer collaboration with strategic partners interested in aligning their product roadmaps with Goliath. In February 2023, Ilika commenced leading a 24-month £8.2 million Faraday Battery Challenge collaboration programme to integrate high silicon content electrodes into its Goliath solid-state batteries to enable automotive level performance. The programme is supported by BMW and Williams Advanced Engineering.

 

Notice of Results

Ilika expects to announce its audited full year results for the year ended 30 April 2023 on Thursday 13 July 2023. 

 

Analyst Briefing

The management team will be hosting an in-person analyst briefing on the day, Thursday 13 July 2023, at 9.30am. Analysts who wish to attend should contact Lianne Applegarth at Walbrook PR on +44(0)20 7933 8780 or email ilika@walbrookpr.com to register.

 

Investor Presentation

An investor presentation will be held on the day, Thursday 13 July 2023, at 4.30pm and will be hosted through the digital platform, Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Ilika plc via the following link: https://www.investormeetcompany.com/ilika-plc/register-investor or for more information please contact Walbrook PR at ilika@walbrookpr.com

 

For more information contact:

For more information contact:

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Liberum Capital Limited (Nomad and Joint Broker)

Tel: 020 3100 2000

Andrew Godber,

William Hall, Nikhil Varghese

Joh. Berenberg, Gossler & Co. KG (Joint Broker)

Tel: 020 3207 8700

Matthew Armitt, Mark Whitmore, Detlir Elezi,

Mara Grasso

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Lianne Applegarth

Mob: 07584 391 303

Nick Rome

Mob: 07748 325 236

Tom Cooper

Mob: 07971 221 972

 

About Ilika plc

Ilika specialises in the development of solid-state batteries. Its Stereax® product line is designed for miniature medical devices and specialist internet of Things (IoT) applications. Stereax® enables disruptive product designers looking for an intrinsically safe, long life (1000s recharges), low leakage (nA) and miniature power source in a rectangular form factor similar to ICs. For more information about Ilika, please visit:  https://www.ilika.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLREEIALIV
Date   Source Headline
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.